Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer
Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the appointment of experienced biotechnology industry executive, Christophe Quéva, Ph.D., as Chief Executive Officer (CEO). With over 20 years of experience in the biotechnology industry, Dr. Quéva brings a wealth of expertise as Egle transitions into the clinic its two lead drug candidates, EGL-001 and EGL-003.
“I am thrilled to join Egle Therapeutics and collaborate with a team renowned for its deep scientific expertise in regulatory T cells and its strong track record in developing innovative drug candidates for immunology and oncology,” said Christophe Quéva, Ph.D. “Egle is uniquely positioned to demonstrate the therapeutic potential of harnessing regulatory T cells for treating both cancer and autoimmune diseases.”
“As we transition from a company with preclinical assets to a fully-fledged clinical-stage biotech, we will benefit greatly from Christophe's deep operational and strategic expertise. We are delighted to welcome Christophe to the Egle team and look forward to the successes he will drive,” said Vincent Brichard, M.D., Egle’s Interim CEO and Board member.
“Christophe’s appointment marks a pivotal moment for Egle, as we focus on clinical development and advancing our technology platform, his experience, knowledge and networks of the sector will ensure Egle continues to shape its future," said Michel Detheux, Chairman of the board.
Christophe Quéva, Ph.D.
Dr. Christophe Quéva brings over two decades of experience in immuno-oncology, spanning portfolio development from target identification to clinical trials and regulatory approvals. Before joining Egle, he founded and led Ovie Therapeutics, a company focused on an innovative treatment for brain cancer. Since 2022, he has also served as Chief Scientific Officer at DEM BioPharma, driving the development of cancer macrophage-targeting therapies. Prior to this, Dr. Quéva was Chief Scientific Officer at Oncorus, where he advanced next-generation immunotherapies using oncolytic viruses and RNA therapeutics. He also held the same role at iTeos Therapeutics, overseeing the development of a groundbreaking immuno-oncology portfolio.
Earlier in his career, Dr. Quéva held leadership roles at Gilead Sciences, Amgen, and AstraZeneca, contributing to oncology and inflammation drug discovery. He holds a Ph.D. in Life and Health Sciences from the University of Lille in France and completed postdoctoral research in cancer biology at the Fred Hutchinson Cancer Research Center. Dr. Quéva’s extensive career includes numerous patents and publications in the oncology field, reflecting his commitment to advancing patient care through innovative science and leadership.
About Egle Therapeutics SAS (Egle)
Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle is evaluating its most advanced drug candidate in oncology, EGL-001 (a Treg-selective anti-CTLA4-IL-2m), in a Phase I/II clinical trial. In autoimmunity, Egle has completed IND-enabling studies for, EGL-003 (an IL-2 Treg engager), and is poised to commence a clinical trial in 2025.
Find out more at www.egle-tx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113580621/en/
Contacts
contact@egle-tx.com / 0033 (0)1 86 64 08 57
investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TriLink BioTechnologies® and Aldevron Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology4.2.2025 23:01:00 EET | Press release
TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Aldevron, a leading, global Contract Development and Manufacturing Organization (CDMO) providing high-quality plasmid DNA, RNA, and proteins for research, therapeutics, and diagnostics. With this agreement with Aldevron, TriLink strengthens its objective to provide greater access to CleanCap® mRNA capping technologies to those developing critical mRNA-based therapeutics and vaccines. According to the terms of the agreement, TriLink will supply its patented CleanCap® M6, CleanCap® AG 3’OMe, CleanCap® AG, and CleanCap® AU cap analogs for use in Aldevron’s mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap® technology produces optimal 5’Cap structures with over 95% efficiency, creating a co-transcriptional capping solution that improves mRNA
Telcoin Granted Approval to Open Nebraska’s First Digital Asset Bank4.2.2025 21:32:00 EET | Press release
Telcoin, a pioneer in blockchain-based financial services, announced that its application to become Nebraska’s first Digital Asset Depository Institution has been conditionally approved by the state’s Department of Banking and Finance. This approval brings Telcoin Bank, a Digital Asset Bank, another step closer to creating the first real bridge between traditional finance and cryptocurrencies. Telcoin Bank is now poised to become the first regulated crypto bank in the United States. Its upcoming launch is expected to disrupt the US$200 billion stablecoin market and transform the financial landscape by offering fully regulated, bank-issued “Digital Cash” stablecoins, as well as an innovative suite of blockchain banking products and services. This development promises to accelerate the adoption of crypto in mainstream finance and provide unparalleled access to digital financial services for mobile phone users worldwide. “This approval marks a major milestone for Telcoin and the entire US
HTEC and AI Inference Hardware Startup, d-Matrix, Announce Strategic Partnership4.2.2025 20:23:00 EET | Press release
HTEC, a global consulting, software, and digital product development company, is proud to announce a strategic partnership with d-Matrix, the creator of Corsair™, the world’s most efficient AI computing platform for inference in datacenters. HTEC Advisory Board member Sasha Ostojic, who also sits on d-Matrix's Board of Directors, was instrumental in connecting the companies and expediting the collaboration. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250204571709/en/ HTEC announces partnership with d-Matrix, the creator of Corsair™, the world’s most efficient AI computing platform for inference in datacenters (Graphic: Business Wire) During their work together, HTEC will leverage its extensive expertise in AI and embedded software development to support d-Matrix in the development of its software solution. Additionally,HTEC will use an active management approach to proactively identify and address issues and robust report
Monroe Capital Hires Galen Fu as Director, Business Development and Opens Australia Office4.2.2025 18:00:00 EET | Press release
Monroe Capital LLC (“Monroe”) today announced it has expanded its platform to Australia with the appointment of Galen Fu as Director, Business Development. Fu will be based in the firm’s Sydney, Australia office and will be responsible for client servicing and capital raising across Australia. Fu has more than 14 years of experience in capital raising, portfolio management and banking in the Asia-Pacific region. Prior to Monroe, he was a Director in the Capital Markets team at Hines Investment Management where he was responsible for business development and investor relations across Australia. He previously held roles at MaxCap Investment Management (a subsidiary of Apollo Global Management), Westpac Bank and ANZ Bank. Fu earned his B.A. in Commerce and Economics from the University of New South Wales. “We have several long-standing limited partners in Australia and we look forward to our continued strategic growth and expansion in Australia,” said Zia Uddin, President of Monroe Capita
NTT DATA, Inc. Appoints Sudhir Chaturvedi as Global Chief Growth Officer and North America CEO4.2.2025 18:00:00 EET | Press release
NTT DATA, a global digital business and IT services leader, today announced that Sudhir Chaturvedi will join NTT DATA, Inc. as its Global Chief Growth Officer and North America Chief Executive Officer. In the newly created Global Chief Growth Officer role, Chaturvedi will lead the acceleration of consistent growth strategies globally, with special focus on global industries, strategic accounts, and joint go-to-market execution with key strategic partners. In his North America CEO role, Chaturvedi will lead NTT DATA Inc.’s growth and business in this strategic region, while leveraging synergies with his Global Chief Growth Officer remit. Chaturvedi succeeds Eric Clark who is leaving the company for a leadership role outside of NTT DATA. Chaturvedi will report to Abhijit Dubey, President and Global CEO of NTT DATA, Inc., and plans to be based in Plano, TX. “Sudhir has a unique blend of expertise across Consulting, IT Services and Software, alongside industry, digital transformation and s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom